• Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Source: Nasdaq GlobeNewswire / 24 Jan 2024 15:15:00   America/Chicago

           
    Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
    Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2023:

    • Cash: € 416,331.34
    • Number of shares: 83,228
    • Number of executions on buy side on semester: 828
    • Number of executions on sell side on semester: 877
    • Traded volume on buy side on semester: 157,508 shares for € 584,045.97
    • Traded volume on sell side on semester: 180,395 shares for € 695,421.23

    At the last half-year report as of June 30, 2023, the following resources were available in the liquidity account:

    • Cash: € 299,865.86
    • Number of shares: 106,115
    • Number of executions on buy side on semester: 1,023
    • Number of executions on sell side on semester: 1,071
    • Traded volume on buy side on semester: 214,181 shares for € 823,005.84
    • Traded volume on sell side on semester: 221,069 shares for € 839,809.73

    When the contract was initially implemented, the following resources were included in the liquidity account:

    • Cash: € 163,510.42
    • Number of shares: 34,063
      Buy Side   Sell Side
      Number of
    executions     		Number of
    shares     		Traded volume in EUR   Number of
    executions     		Number of
    shares     		Traded volume in EUR
    Total 828 157 508 584 045,97   877 180 395 695 421,23
    07/03/2023 - - -   6 750 2 827,50
    07/04/2023 4 750 2 782,50   2 750 2 827,50
    07/05/2023 8 1 750 6 545,00   4 287 1 107,82
    07/06/2023 12 2 500 9 000,00   1 1 3,76
    07/07/2023 2 750 2 632,50   8 1 250 4 487,50
    07/10/2023 - - -   13 3 462 13 155,60
    07/11/2023 4 250 960,00   7 1 250 4 850,00
    07/12/2023 2 750 2 857,50   7 500 1 915,00
    07/13/2023 4 250 947,50   3 1 000 3 800,00
    07/14/2023 6 750 2 782,50   3 362 1 375,60
    07/17/2023 9 2 250 8 235,00   6 1 039 3 885,86
    07/18/2023 3 500 1 810,00   8 1 999 7 476,26
    07/19/2023 15 574 2 158,24   3 450 1 714,50
    07/20/2023 12 2 426 8 879,16   2 250 940,00
    07/21/2023 5 1 000 3 620,00   6 748 2 752,64
    07/24/2023 9 2 000 7 120,00   6 301 1 095,64
    07/25/2023 13 2 913 9 816,81   15 2 100 7 140,00
    07/26/2023 9 2 349 8 080,56   9 2 250 7 830,00
    07/27/2023 4 1 250 4 475,00   17 4 551 16 565,64
    07/28/2023 5 1 000 3 570,00   6 750 2 700,00
    07/31/2023 - - -   10 1 962 7 337,88
    08/02/2023 11 2 500 9 125,00   - - -
    08/03/2023 1 500 1 800,00   - - -
    08/04/2023 3 1 000 3 600,00   5 511 1 880,48
    08/07/2023 2 500 1 810,00   - - -
    08/08/2023 3 1 000 3 600,00   1 250 915,00
    08/09/2023 1 250 885,00   2 500 1 800,00
    08/10/2023 5 501 1 773,54   1 250 890,00
    08/11/2023 10 1 249 4 309,05   7 1 137 3 990,87
    08/14/2023 6 1 500 5 235,00   2 251 881,01
    08/15/2023 12 1 750 6 002,50   - - -
    08/16/2023 - - -   1 500 1 700,00
    08/17/2023 10 501 1 673,34   4 251 843,36
    08/18/2023 6 750 2 475,00   - - -
    08/21/2023 2 136 454,24   6 1 031 3 484,78
    08/22/2023 4 314 1 058,18   4 969 3 304,29
    08/23/2023 6 1 000 3 400,00   5 1 250 4 300,00
    08/24/2023 5 1 000 3 360,00   1 1 3,46
      Buy Side   Sell Side  
      Number of
    executions     		Number of
    shares     		Traded volume in EUR   Number of
    executions     		Number of
    shares     		Traded volume in EUR  
    Total 828 157 508 584 045,97   877 180 395 695 421,23  
    08/25/2023 6 1 238 4 060,64   - - -  
    08/28/2023 2 36 116,64   1 500 1 665,00  
    08/29/2023 3 214 693,36   3 133 438,90  
    08/30/2023 7 1 000 3 200,00   2 185 592,00  
    08/31/2023 - - -   55 15 157 57 899,74  
    09/01/2023 1 250 835,00   8 2 000 7 620,00  
    09/04/2023 3 750 2 632,50   - - -  
    09/05/2023 3 500 1 750,00   - - -  
    09/06/2023 5 1 500 5 145,00   1 500 1 820,00  
    09/07/2023 5 1 250 4 187,50   - - -  
    09/08/2023 1 1 3,40   3 251 853,40  
    09/11/2023 5 500 1 670,00   8 1 250 4 237,50  
    09/12/2023 6 1 651 5 514,34   - - -  
    09/13/2023 - - -   30 7 311 26 319,60  
    09/14/2023 - - -   9 1 439 5 381,86  
    09/15/2023 1 500 1 850,00   7 750 2 842,50  
    09/18/2023 10 2 500 9 275,00   6 1 500 5 610,00  
    09/19/2023 13 1 823 6 672,18   6 1 100 4 070,00  
    09/20/2023 3 777 2 804,97   7 1 000 3 690,00  
    09/21/2023 14 2 250 9 135,00   37 9 250 39 775,00  
    09/22/2023 1 500 1 945,00   13 2 500 10 300,00  
    09/25/2023 4 1 000 4 300,00   8 2 750 12 072,50  
    09/26/2023 17 3 500 14 980,00   18 4 150 18 218,50  
    09/27/2023 14 3 000 12 510,00   6 1 011 4 377,63  
    09/28/2023 25 4 750 18 715,00   14 3 871 15 522,71  
    09/29/2023 2 500 2 050,00   17 3 369 13 880,28  
    10/02/2023 6 1 500 6 195,00   10 2 000 8 480,00  
    10/03/2023 20 2 175 8 743,50   1 250 1 015,00  
    10/04/2023 8 1 475 5 826,25   6 1 000 3 990,00  
    10/05/2023 10 2 750 10 725,00   7 750 2 970,00  
    10/06/2023 6 1 368 5 307,84   11 2 000 7 880,00  
    10/09/2023 13 2 882 10 922,78   4 751 2 876,33  
    10/10/2023 8 1 750 6 422,50   - - -  
    10/11/2023 5 1 000 3 600,00   3 501 1 808,61  
    10/12/2023 5 1 001 3 693,69   11 1 951 7 277,23  
    10/13/2023 - - -   6 750 2 842,50  
    10/16/2023 7 1 194 4 405,86   - - -  
    10/17/2023 17 3 256 11 428,56   4 850 3 009,00  
      Buy Side   Sell Side  
      Number of
    executions     		Number of
    shares     		Traded volume in EUR   Number of
    executions     		Number of
    shares     		Traded volume in EUR  
    Total 828 157 508 584 045,97   877 180 395 695 421,23  
    10/18/2023 8 1 500 5 205,00   - - -  
    10/19/2023 14 2 750 9 350,00   3 510 1 749,30  
    10/20/2023 19 1 500 5 055,00   - - -  
    10/23/2023 11 2 750 8 800,00   19 2 500 8 175,00  
    10/24/2023 - - -   16 2 640 9 108,00  
    10/25/2023 7 2 000 6 880,00   1 1 3,44  
    10/26/2023 6 750 2 527,50   8 1 749 5 981,58  
    10/27/2023 5 279 976,50   7 1 251 4 378,50  
    10/30/2023 2 379 1 334,08   8 1 849 6 582,44  
    10/31/2023 8 1 000 3 600,00   4 500 1 805,00  
    11/01/2023 6 1 356 4 718,88   1 1 3,59  
    11/02/2023 3 500 1 750,00   2 500 1 820,00  
    11/03/2023 - - -   2 250 915,00  
    11/06/2023 7 1 750 6 387,50   7 1 982 7 472,14  
    11/07/2023 10 2 250 8 302,50   21 4 017 15 385,11  
    11/08/2023 7 1 250 4 525,00   6 622 2 282,74  
    11/09/2023 4 1 250 4 437,50   1 1 3,66  
    11/10/2023 19 2 750 9 432,50   1 250 860,00  
    11/13/2023 11 1 512 5 201,28   6 1 000 3 460,00  
    11/14/2023 3 988 3 408,60   10 1 999 7 076,46  
    11/15/2023 8 1 956 6 826,44   5 750 2 632,50  
    11/16/2023 9 1 744 6 016,80   5 1 500 5 250,00  
    11/17/2023 - - -   3 750 2 692,50  
    11/20/2023 10 1 000 3 640,00   16 3 678 13 608,60  
    11/21/2023 9 2 000 7 320,00   6 1 000 3 690,00  
    11/22/2023 3 500 1 835,00   13 2 127 7 912,44  
    11/23/2023 8 1 633 6 009,44   5 1 473 5 567,94  
    11/24/2023 4 617 2 282,90   1 250 930,00  
    11/27/2023 2 1 000 3 800,00   16 5 500 21 450,00  
    11/28/2023 5 2 000 7 840,00   3 1 500 5 955,00  
    11/29/2023 6 1 022 3 955,14   7 2 500 9 775,00  
    11/30/2023 26 4 478 17 016,40   - - -  
    12/01/2023 5 1 501 5 643,76   9 2 501 9 553,82  
    12/04/2023 - - -   5 1 500 5 925,00  
    12/05/2023 6 2 000 8 180,00   21 4 501 18 499,11  
    12/06/2023 2 500 2 050,00   13 2 999 12 475,84  
    12/07/2023 - - -   10 2 500 10 500,00  
    12/08/2023 4 1 000 4 200,00   1 500 2 105,00  
      Buy Side   Sell Side  
      Number of
    executions     		Number of
    shares     		Traded volume in EUR   Number of
    executions     		Number of
    shares     		Traded volume in EUR  
    Total 828 157 508 584 045,97   877 180 395 695 421,23  
    12/11/2023 6 1 000 4 170,00   5 1 252 5 283,44  
    12/12/2023 28 5 500 21 835,00   11 1 001 4 014,01  
    12/13/2023 5 1 500 5 835,00   6 249 986,04  
    12/14/2023 2 501 1 953,90   7 1 000 3 910,00  
    12/15/2023 7 1 499 5 756,16   3 762 2 964,18  
    12/18/2023 - - -   3 488 1 903,20  
    12/19/2023 6 501 1 963,92   1 250 982,50  
    12/20/2023 1 1 3,94   18 3 949 16 151,41  
    12/21/2023 19 3 050 12 291,50   17 1 750 7 157,50  
    12/22/2023 7 900 3 681,00   16 3 250 13 617,50  
    12/27/2023 6 1 100 4 631,00   14 3 400 14 484,00  
    12/28/2023 8 2 150 8 965,50   7 1 750 7 420,00  
    12/29/2023 7 1 537 6 301,70   4 450 1 845,00  

    About Inventiva

    Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

    Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

    Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

    The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

    Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

    Contacts

    Inventiva

    Pascaline Clerc, PhD

    EVP, Strategy and Corporate Affairs

    media@inventivapharma.com

    +1 202 499 89375     		Brunswick Group

    Tristan Roquet Montegon /

    Aude Lepreux /

    Matthieu Benoist

    Media relations

    inventiva@brunswickgroup.com

    +33 1 53 96 83 83     		Westwicke, an ICR Company

    Patricia L. Bank

    Investor relations

    patti.bank@westwicke.com

         +1 415 513-1284     		           

    Important Notice

    This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, expectations with respect to clinical trials, regulatory plans, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in patients with NASH and anticipated results and timing thereof, the potential development of and regulatory pathway for odiparcil, the potential therapeutic benefits of Inventiva’s product candidates, Inventiva’s future activities, expectations, plans, growth and prospects, Inventiva’s ability to exercise its rights under the Finance Contract and warrant agreement with the EIB, including its call right and right of first refusal, expectations with respect to EIB’s rights under the agreements and EIB’s potential exercise of warrants, the expected use of proceeds from the EIB facility, Inventiva's ability to repay the EIB loans and the timing thereof, and the sufficiency of Inventiva’s cash resources and cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “possible,” “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva’s expectations with respect to the changes to the clinical development plan for lanifibranor for the treatment of NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

    Please refer to the Universal Registration Document for the year ended December 31, 2022 filed with the Autorité des Marchés Financiers on March 30, 2023 as amended on August 31, 2023, the Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 30, 2023, and the Half-Year Report for the six months ended June 30, 2023 on Form 6-K filed with the SEC on October 3, 2023, for other risks and uncertainties affecting Inventiva, including those described from time to time under the caption “Risk Factors”. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statement.

     

    Attachment


Share on,